- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03605927
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Cancer Center
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Hematologic malignancy or blood disorder requiring allogeneic HCT
- Adequate vital organ function as defined per protocol
- Karnofsky Performance Status Score (KPS) ≥ 80%
- Participants must have an available 8/8 HLA-A, -B, -C, and -DRB1 matched-related or unrelated donor
Exclusion Criteria:
- Active infection not controlled with appropriate antimicrobial therapy
- HIV, hepatitis B or C infection or known history of HIV, hepatitis B or C(all patients will be tested for HIV, hepatitis B and C as part of standard pre-transplant testing, and will be excluded from this trial if positive)
- Anti-thymocyte globulin, or cyclophosphamide administered within 14 days before or planned to receive with HCT conditioning or as part of GVHD prophylaxis in the 14 days after HCT
- Known allergic reactions to components of the study drug
- Concurrent treatment with another investigational drug
- History of thromboembolism, transient ischemic attack, stroke, myocardial infarction within 3 months preceding the transplant, or uncontrolled congestive heart failure or cardiac arrhythmias.
- Post-transplant maintenance therapies such as FLT3 inhibitor, tyrosine kinase inhibitor, JAK inhibitors etc. are not allowed if plan is to initiate such therapies <90 days post-transplant. Patient will be eligible if plan to initiate maintenance therapy is after day 90 post-transplant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination Therapy
BMS-986004: From day 13, intravenously (IV) every 2 week through day 100 post HCT. Tacrolimus: From day -3 as standard of care. Sirolimus: From day -1 as standard of care. |
BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial.
Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined.
BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT.
The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended dose level in the phase 1 expansion cohort.
Other Names:
Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards. Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range. Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions.
Other Names:
Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards. In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL. Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Grade II-IV Acute Graft-versus Host Disease
Time Frame: 1 year post HCT
|
Cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) by day 100 after hematopoietic cell transplantation (HCT).
Acute GVHD severity will be determined by standard Consensus Criteria, and the cumulative incidence of grade II-IV acute GVHD will be reported through day 100 post-HCT, with relapse and death as competing risk events.
|
1 year post HCT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chronic Graft-versus Host Disease Through 1 Year Post HCT
Time Frame: 1 year post HCT
|
NIH criteria defined chronic graft-versus-host disease through 1 year post-HCT.
Chronic GVHD will be defined by the presence of chronic GVHD defining features, regardless of time post-HCT, in keeping with the NIH Consensus Criteria on diagnosis and staging of chronic GVHD.
Individual affected organs are staged on 0-3 severity scale, and summarized for an overall global severity score.
The presence of acute GVHD features defines the following subgroups: (1) late acute GVHD (sole presence of acute GVHD features after day 100 post-HCT), (2) overlap subtype of chronic GVHD (co-occurrence of chronic and acute GVHD features, and (3) classic chronic GVHD (absence of concurrent acute GVHD features).
|
1 year post HCT
|
Malignancy Relapse Post-HCT
Time Frame: 1 year post HCT
|
Defined as hematologic relapse or any unplanned intervention (including withdrawal of immune suppression) to prevent progression of disease in patients with evidence (molecular, cytogenetic, flow cytometric, radiographic) of malignant disease after HCT.
|
1 year post HCT
|
Non-relapse Mortality
Time Frame: 1 year post HCT
|
Defined as death in the absence of malignancy relapse post-HCT.
|
1 year post HCT
|
Overall Survival (OS)
Time Frame: 1 year post HCT
|
Defined as time from HCT to death or censoring for last follow up.
|
1 year post HCT
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucocorticoid Exposure
Time Frame: 1 year post HCT
|
Systemic steroid (prednisone or equivalent) dose per kg of recipient body weight will be collected at each study visit, and overall exposure determined.
|
1 year post HCT
|
Neutrophil and Platelet Engraftment
Time Frame: 1 year post HCT
|
Stable engraftment is defined as a sustained absolute neutrophil count > 500 over 3 days, as well as a sustained platelet count of > 20 over 7 days without transfusion support.
Time to engraftment is defined as time from day 0 to day of sustained engraftment per above criteria.
|
1 year post HCT
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Farhad Khimani, M.D., H. Lee Moffitt Cancer Center and Research Institute
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Graft vs Host Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Calcineurin Inhibitors
- Tacrolimus
- Sirolimus
Other Study ID Numbers
- MCC-19305
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GVHD
-
Shanghai Jiao Tong University School of MedicineCompleted
-
MaaT PharmaRecruitingSteroid Refractory GVHD | Intestinal GVHDFrance
-
Mats RembergerThe Swedish Research CouncilRecruitingGVHD, AcuteSweden, Norway, Denmark
-
Weill Medical College of Cornell UniversityTerminatedGlucocorticosteroid Refractory Acute GVHDUnited States
-
CSL BehringTerminated
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
daphne brockingtonUnknownChronic GVHD After HCT for Cancer or Immune DiseaseCanada
-
Nationwide Children's HospitalDaisy FoundationCompletedGVHD | Hematopoietic Stem Cell TransplantUnited States
-
Duke UniversityRecruiting
-
University of SalamancaRecruitingGVHD, Chronic | GVHD,AcuteSpain
Clinical Trials on BMS-986004
-
Bristol-Myers SquibbCompletedImmune Thrombocytopenic PurpuraUnited States, Australia, United Kingdom, Canada, Georgia, Moldova, Republic of, Poland, Russian Federation
-
China National Center for Cardiovascular DiseasesPeking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical...UnknownCoronary Artery EctasiaChina
-
CelgeneRecruitingProstatic NeoplasmsUnited States
-
Bristol-Myers SquibbCompletedHeart FailureUnited States
-
Bristol-Myers SquibbRecruitingProgressive Pulmonary FibrosisChina, Japan, United States, Hungary, Canada, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Portuga... and more
-
Bristol-Myers SquibbRecruitingIdiopathic Pulmonary FibrosisChina, Taiwan, United States, Australia, Japan, United Kingdom, Korea, Republic of, Israel, Canada, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, ... and more
-
Bristol-Myers SquibbRecruiting
-
Bristol-Myers SquibbCompletedHeart Decompensation, AcuteUnited States
-
Bristol-Myers SquibbRecruitingHealthy Male VolunteersUnited States
-
Bristol-Myers SquibbCompletedPulmonary FibrosisCanada, France, United States, Argentina, Australia, Belgium, Brazil, Chile, China, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Spain, Taiwan, United Kingdom